## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re the Application of:

Piero DEL SOLDATO

Attorney Docket Number: 026220-00043

Serial Number: 10/736,688

Confirmation Number: 4141

Filed: December 17, 2003

Group Art Unit: 1626

For: NITRIC ESTERS AND NITRATE SALTS OF SPECIFIC DRUGS

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

February 6, 2006

Sir:

Pursuant to 37 CFR §1.56, the attention of the U.S. Patent and Trademark Office is hereby directed to the information items listed on the attached PTO/SB/08a and PTO/SB/08b. Unless otherwise indicated herein, one copy of each item is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the items be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

merits	This Information Disclosure Statement is being filed (a) within three months U.S. filing date, OR (b) before the mailing date of a first Office Action on the in the present application, OR (c) accompanies a Request for Continued nation. No certification or fee is required.
	This Information Disclosure Statement is being filed more than three months he U.S. filing date AND after the mailing date of the first Office Action on the , but before the mailing date of a Final Rejection or Notice of Allowance.
	a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
	b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement 37 CFR §1.97(e)(2)

- This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicants hereby petition that the Information Disclosure Statement be considered. Attached is our check number in the amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account Number 01-2300, referencing Attorney Docket Number , as needed to ensure consideration of the disclosed information.
  - a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
  - b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
- 4. Copies of the U.S. patent references are not enclosed in view of the recent changes in U.S. patent rules effective October 21, 2004.

Respectfully submitted,

Amy E.L. Schoenhard

Régistration Number 46.512

Customer Number 004372 ARENT FOX PLLC 1050 Connecticut Avenue, NW Suite 400 Washington, DC 20036-5339 Telephone: 202-857-6000

Fax: 202-857-6395

ALS:vmh

Enclosures: PTO/SB/08a

PTO/SB/08b References (5) U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/736,688 \*\*NFORMATION DISCLOSURE December 17, 2003 Filing Date ATEMENT BY APPLICANT First Named Inventor Piero DEL SOLDATO Form PTO/SB/08a Art Unit 1626 **Examiner Name** Ebenezer O. Sackey of Attorney Docket Number 026220-00043

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	<u>.</u>	US-4,996,061	B1	02-26-1991	Norval E. WEBB et al.	
		US-5,419,898	B1	05-30-1995	Yoshifumi IKEJIRI et al.	
		US-5,429,825	B1	07-04-1995	Joseph P. REO et al.	
		US-5,458,879	B1	10-17-1995	Nikhilesh N. SINGH et al.	
		US-5,708,023	B1	01-13-1998	Shanta M. MODAK et al.	
		US-5,861,426	B1	01-19-1999	Piero DEL SOLDATO et al.	
		US-6,171,618	B1	01-09-2001	Barbara A. JOHNSON et al.	
		US-6,258,816	B1	07-10-2001	Amarjit SINGH et al.	
		US-6,489,329	B2	12-03-2002	Herman VAN DE VENNE et al.	
		US-6,613,784	B1	09-02-2003	Francesca BENEDINI et al.	
		US-6,869,974	B1	03-22-2005	Piero DEL SOLDATO	
		US-6,987,120	B1	01-17-2006	Piero DEL SOLDATO	
		US-				
		US-				
		US-				
		US-				
		US-				
•		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Country Code <sup>3</sup>	Number⁴ Kind Code⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		WO 95/07103	wo	A1	03-16-1995	Sekhar MITRA		Γ
		WO 98/00159	wo	A1	01-08-1998	Ronald W. PERO		
		WO 99/32125	WO	A1	07-01-1999	Peder K. JENSEN et al.		
<del></del>	ļ				·			
								<u> </u>
								<u> </u>
·								

Examiner	Date	
	Date	
Signature	Considered	
_ Oignature		
		·

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO	Complete if Known				
MEORMATION DISCLOSURE	Application Number	10/736,688			
	Filing Date	December 17, 2003			
STATEMENT BY APPLICANT Form PTO/SB/08b	First Named Inventor	Piero DEL SOLDATO			
F FORM P10/3B/06B	Art Unit	1626			
<b>.&amp;</b> /	Examiner Name	Ebenezer O. Sackey			
1 of 1	Attorney Docket Number	026220-00043			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		F. Geroge NJOROGE et al., "Highly Regioselective Nitration Reactions Provide A Versatile Method of Functionalizing Benzocycloheptapyridine Tricyclic Ring Systems: Application toward Preparation of Nanomolar Inhibitors of Farnesyl Protein Transferase," J. Org. Chem., Vol. 63, No. 3, 1998, pages 445-451	
		A.F.M. El WALILY, "Spectrophotometric and high performance liquid chromatographic determination of cetirizine dihydrochloride in pharmaceutical tablets," Journal of Pharmaceutical and Biomedical Analysis 17, 1998, pages 435-442	
	<u> </u>		-
			<del> </del>
	ļ		
· · · · · · · · · · · · · · · · · · ·			
	<u> </u>		1
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.